Healio

Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Healio

FDA approves subcutaneous Entyvio as maintenance therapy for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Nasdaq

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...
Monthly Prescribing Reference

Entyvio for Subcutaneous Use Approved for Maintenance in Crohn Disease

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...
FiercePharma

In 2nd attempt, Takeda scores FDA nod for subcutaneous version of Entyvio

In 2020, Europe endorsed a subcutaneous version of Takeda's Entyvio. More than three years later, the Japanese company has finally won over the FDA with its SC formulation. (Takeda) Nearly four years ...
Nasdaq

European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis ...

− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − ...
News Medical

Entyvio Pen

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Entyvio pre-filled pen for subcutaneous injection contains the active ...
markets.financialcontent

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. − ENTYVIO is Now Available in the U.S. in Both IV and ...
streetinsider

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease OSAKA, ...
streetinsider

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

“With the FDA approval of subcutaneous ENTYVIO, patients and physicians who want ENTYVIO’s clinical profile along with flexibility of administration now have two choices for maintenance treatment for ...